RxDoctor Payments Data

Olga Waln, MD

Neurology · Houston, TXNPI 1013133768

Payments from drug & device makers

$540,959in general payments, 2019–2025

Across 790 payments — averaging $684.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB SA$375K
  • Sage Therapeutics, LLC$61K
  • Acadia Pharmaceuticals Inc$40K
  • Merz Pharmaceuticals, LLC$38K
  • Neurocrine Biosciences, Inc.$8K
  • Amneal Pharmaceuticals LLC$6K
  • plus $12K from 49 others
$24,740in research payments, 2019–2025

Across 4 payments — averaging $6185.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Acadia Pharmaceuticals Inc$22K
  • Merz Pharmaceuticals, LLC$2K
  • Neurocrine Biosciences, Inc.$400

What the payments were for

  • Consulting fees$8,99929%
  • Speaking & faculty fees$5,53918%
  • Travel & lodging$1,4275%
  • Food & beverage$14,64548%
  • Education$940%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$540,959 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$334,448
Medicare patients
391
Services billed
29,362

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine89$937,281
NuplazidPimavanserin Tartrate87$600,908
IngrezzaValbenazine Tosylate53$409,547
RytaryCarbidopa/Levodopa162$233,327
NourianzIstradefylline27$96,359
BotoxOnabotulinumtoxina54$92,481
InbrijaLevodopa17$79,407
GocovriAmantadine Hcl25$76,986
Tetrabenazine17$31,558
Carbidopa-LevodopaCarbidopa/Levodopa840$31,205
NuedextaDextromethorphan Hbr/Quinidine14$29,692
NeuproRotigotine18$14,720
Rasagiline Mesylate111$12,969
Ropinirole ErRopinirole Hcl56$9,374
Pramipexole ErPramipexole Di-Hcl25$9,121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$935$937,28189 claims
Acadia Pharmaceuticals IncNuplazid$39,738$600,90887 claims
Neurocrine Biosciences, Inc.Ingrezza$8,313$409,54753 claims
Amneal Pharmaceuticals LLCRytary$6,335$233,327162 claims
Kyowa Kirin, Inc.Nourianz$219$96,35927 claims
AbbVieBotox$1,975$92,48154 claims
Acorda Therapeutics, IncInbrija$954$79,40717 claims
MDD US Operations, LLCGocovri$355$76,98625 claims
Avanir Pharmaceuticals, Inc.Nuedexta$57$29,69214 claims
UCB, Inc.Neupro$15$14,72018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,246 neurology providers in Texas.

Other neurology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →